Incyte (INCY) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Incyte (INCY)

INCY 60.98

+0.3%

2:45 PM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: former_pgs who wrote (3155)	1/9/2018 3:29:40 PM
From: scaram(o)uche	Read Replies (1) of 3202

These findings are important translationally, because they suggest broader clinical uses for D-1MT against cancers that overexpress any tryptophan catabolic enzyme (IDO1, IDO2 or TDO). ncbi.nlm.nih.gov >> does suggest one would make a mistake by extrapolating heavily based on the indoximod data << Yeah, but a mistake in which direction?? Isn't downstream inhibition of IDO1, IDO2 and TDO better than IDO1 alone?? The Incyte rationale for IOD1 selective agents is given here, third paragraph..... ncbi.nlm.nih.gov So they would say "no".

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next